Replies to post #44697 on $.0001-$.0011 News, DDs & Charts Only!!!

[mick]

Tenax Therapeutics (NASDAQ: TENX): Near-Term Phase 2 Results Expected to Drive Stock

Exclusive interview with Tenax Therapeutics (NASDAQ: TENX) CEO Anthony Ditonno.TENX is expected to report Phase 2 results for its pulmonary hypertension treatment by year end. Its innovative treatment is based on an established compound, approved in 60+ countries and cited in 1000+ publications, which provides a strong foundation that de-risks the development opportunity.